Topline data: In the non-randomized AVG cohort (n=112) of Merit Medical’s WAVE trial, WRAPSODY Cell-Impermeable Endoprosthesis achieved a 6-month target lesion primary patency of 81.4% versus a 60% historical performance goal (p<0.0001). Target lesion patency was 60.2% at 12 months and 41.7% at 24 months. Access circuit primary patency was 36.2% at 12 months and 25.7% at 24 months. Merit reported 24-month efficacy from the AVG cohort at the VEINS late-breaking session, drawing on outcomes from 43 centers across the United States, South America, and the United Kingdom. The study evaluates WRAPSODY in hemodialysis patients with stenosis or occlusion of an arteriovenous graft, using target-lesion and access-circuit patency as functional endpoints. The device, which received FDA premarket approval in December 2024 and Health Canada approval in April 2025 following prior CE Marking, is being followed in prospective real-world registries in North America and globally to extend post-market evidence. Strategically, the data illustrate a familiar device-development pattern in endovascular access: establish a strong early signal against performance goals to secure approval, then lean on longer-term follow-up and real-world registries to validate durability and inform positioning against entrenched options.
The robust six-month result provides the commercial foothold; the 12- and 24-month patency attrition underscores the biology of AVG failure and the bar that any endoprosthesis must clear to shift practice earlier in the treatment algorithm. Without head-to-head randomized comparisons with covered stents or DCB-based strategies in graft lesions, the non-randomized design will limit comparative claims, placing greater weight on subsequent registry readouts and health-economic analyses. For interventional sites, the signal suggests a tool that could reduce target-lesion reinterventions over the first year, with less pronounced impact at the circuit level. That has practical implications for lab throughput, surveillance intervals, and stock decisions. Still, the lack of randomized comparators means formulary committees will likely request local utilization audits and payor feedback before widespread adoption. For sponsors and CROs, WAVE’s endpoint framework and geographic footprint reflect where regulators and clinicians are converging on dialysis access evidence: lesion-level durability, circuit functionality, and time-to-reintervention, tracked beyond 12 months and increasingly corroborated by real-world registries. Regulators are likely to view the ongoing WRAP North America Registry (targeting up to 250 patients) and the WRAP Global registry as important for confirming external validity and safety-event profiles in routine practice. What to watch next is whether registry outputs quantify the burden of reintervention, thrombosis, and infection rates, and whether economic endpoints are tightly enough defined to influence payer policy and guideline updates. Subgroup analyses—central versus peripheral lesions, thrombotic versus purely stenotic pathology, and prior device exposure—will matter for procedural planning and selection criteria. Competitive dynamics will be active, with incumbent covered stents and maturing DCB data shaping site preferences; any randomized evidence, even pragmatic in design, would accelerate clarity on positioning. Reimbursement and site-of-service pressures will also shape adoption, particularly as dialysis access procedures move between hospital outpatient and ASC settings. Over the next 12–18 months, the pivot from strong early patency to demonstrable, cost-relevant durability will determine whether WRAPSODY becomes a default option for failing AV grafts or remains a targeted solution within a still-fragmented treatment pathway.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
